Locally advanced cervical cancer
Prepared with OnCo (onco.cc/prep/locally-advanced-cervical-cancer/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
22 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example FIGO 2018 stage including nodal status on PET-CT, Tumour volume on MRI, Para-aortic node involvement, Haemoglobin before and during radiotherapy, HPV type and p16), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (standard chemoradiation), which of the standard options do you recommend and why?
- 6.Am I a candidate for Cisplatin, and what side effects should I expect?
- 7.For my situation (high-risk disease (node-positive ib2 to iib, iii to iva)), which of the standard options do you recommend and why?
- 8.Am I a candidate for Pembrolizumab, Cisplatin, and what side effects should I expect?
- 9.How do the results of KEYNOTE-A18 / ENGOT-cx11 / GOG-3047 apply to someone like me?
- 10.For my situation (induction option), which of the standard options do you recommend and why?
- 11.Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, and what side effects should I expect?
- 12.How do the results of INTERLACE apply to someone like me?
- 13.For my situation (not recommended), which of the standard options do you recommend and why?
- 14.Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, and what side effects should I expect?
- 15.How do the results of OUTBACK / ANZGOG 0902 / GOG-0274 apply to someone like me?
- 16.For my situation (staging), which of the standard options do you recommend and why?
- 17.For my situation (central pelvic recurrence after radiotherapy), which of the standard options do you recommend and why?
- 18.Are there clinical trials I could join, for example of HPV circulating tumour DNA to guide cervical cancer therapy, Pembrolizumab, Proton therapy, MRD / molecular residual disease testing?
- 19.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 20.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 21.I read that “Whether induction chemotherapy and pembrolizumab should be combined”. How does that affect my plan?
- 22.I read that “Access to brachytherapy and PET-CT where most patients live”. How does that affect my plan?
The words I may hear
- Laparoscopy (keyhole surgery): Operating or looking inside the abdomen through a few small holes with a camera, instead of one large incision.
- Radiotherapy: Using high-energy X-rays or particles to damage the DNA of cancer cells in a precisely aimed volume of the body.
- Chemoradiation (chemoradiotherapy, CRT): Radiotherapy given at the same time as chemotherapy, which sensitises the cancer to radiation.
Tests and results to bring
Staging: Pelvic MRI and whole-body PET-CT; surgical para-aortic staging in selected cases.
Biomarker results to ask for: FIGO 2018 stage including nodal status on PET-CT, Tumour volume on MRI, Para-aortic node involvement, Haemoglobin before and during radiotherapy, HPV type and p16, PD-L1 (not required for pembrolizumab in this setting), Circulating HPV DNA after treatment (investigational).
Scans and tests linked to this cancer: MRI, PET/CT, MRD / molecular residual disease testing.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- High-risk disease (node-positive IB2 to IIB, III to IVA): Pembrolizumab with chemoradiation and for up to two years afterwards (KEYNOTE-A18). (Pembrolizumab, KEYNOTE-A18 / ENGOT-cx11 / GOG-3047, PD-1 blockade + chemoradiation (locally advanced cervical cancer), Cisplatin, Brachytherapy)
- Standard chemoradiation: Weekly cisplatin with pelvic external-beam radiotherapy followed by image-guided brachytherapy, completed within eight weeks. (Cisplatin, IMRT / IGRT (modern external beam), Brachytherapy, Chemoradiation (chemoradiotherapy, CRT), Radiotherapy)
- Induction option: Six weekly cycles of carboplatin-paclitaxel before chemoradiation (INTERLACE), particularly where immunotherapy is not available. (Carboplatin, Paclitaxel / nab-paclitaxel, INTERLACE, Induction chemotherapy → chemoradiation (locally advanced cervical cancer))
- Not recommended: Adjuvant carboplatin-paclitaxel after chemoradiation gave no benefit in OUTBACK. (OUTBACK / ANZGOG 0902 / GOG-0274, Carboplatin, Paclitaxel / nab-paclitaxel)
- Central pelvic recurrence after radiotherapy: Pelvic exenteration in selected patients; re-irradiation with brachytherapy or protons in specialist centres. (Brachytherapy, Proton therapy, Robotic & minimally invasive surgery)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.